Seelos Therapeutics Management

Management Kriterienprüfungen 3/4

Seelos Therapeutics CEO ist Raj Mehra , ernannt in Jan 2019, hat eine Amtszeit von 5.83 Jahren. Die jährliche Gesamtvergütung beträgt $1.73M , bestehend aus 34% Gehalt und 66% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.33% der Aktien des Unternehmens, im Wert von $715.76 . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.5 Jahre bzw. 5.8 Jahre.

Wichtige Informationen

Raj Mehra

Geschäftsführender

US$1.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	34.0%
Amtszeit als Geschäftsführer	5.8yrs
Eigentum des Geschäftsführers	0.3%
Durchschnittliche Amtszeit des Managements	4.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Raj Mehra im Vergleich zu den Einnahmen von Seelos Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	US$4m
Mar 31 2024	n/a	n/a	-US$27m
Dec 31 2023	US$2m	US$587k	-US$38m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$73m
Dec 31 2022	US$2m	US$562k	-US$74m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$73m
Mar 31 2022	n/a	n/a	-US$61m
Dec 31 2021	US$16m	US$523k	-US$66m
Sep 30 2021	n/a	n/a	-US$45m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$4m	US$475k	-US$19m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$709k	US$438k	-US$51m

Vergütung im Vergleich zum Markt: RajDie Gesamtvergütung ($USD1.73M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD652.28K).

Entschädigung vs. Einkommen: RajDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Raj Mehra (64 yo)

5.8yrs

Amtszeit

US$1,726,476

Vergütung

Dr. Raj Mehra, Ph D., J.D., serves as Chairman at Seelos Therapeutics, Inc. and serves as Chief Executive Officer, Director and President of Seelos Therapeutics, Inc. since January 24, 2019. He was an Inde...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Raj Mehra	CEO, Founder	5.8yrs	US$1.73m	0.33% $ 715.8
Michael Golembiewski	Chief Financial Officer	3.2yrs	US$846.67k	0.16% $ 336.1
Anthony Marciano	Chief Communications Officer	5.8yrs	keine Daten	keine Daten
Gopal Krishna	Head of Manufacturing & Technical Operations	no data	keine Daten	keine Daten
Tim Whitaker	Chief Medical Officer	no data	keine Daten	keine Daten
Karen Fusaro	Senior VP & Head of Clinical Operations	2yrs	keine Daten	keine Daten

4.5yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: SEEL.QDas Führungsteam des Unternehmens gilt als erfahren (4.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Raj Mehra	CEO, Founder	5.8yrs	US$1.73m	0.33% $ 715.8
Margaret Dalesandro	Independent Director	3.2yrs	US$89.72k	0.0021% $ 4.4
Richard Pascoe	Independent Director	11.7yrs	US$87.72k	0.00023% $ 0.5
Brian Lian	Independent Director	5.8yrs	US$105.22k	0% $ 0

5.8yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: SEEL.QDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).

Seelos Therapeutics Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

Chief Financial Officer recently bought US$100k worth of stock

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought US$57k worth of stock

High number of new and inexperienced directors

Recent updates

Seelos Therapeutics, Inc. Filed for Bankruptcy

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market

Nasdaq to Delist Common Stock of Seelos Therapeutics

Nasdaq to Delist Common Stock of Seelos Therapeutics

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

New major risk - Market cap size

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

New major risk - Revenue and earnings growth

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Consensus EPS estimates upgraded to US$0.41 loss

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Chief Financial Officer recently bought US$100k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.34 loss

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 26%

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Consensus revenue estimates increase by 80%, EPS downgraded

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

Price target decreased by 12% to US$5.50

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Price target decreased to US$5.80

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos: Data This Year Is Critical

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos wins Parkinson’s research grant for gene therapy program

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Price target decreased to US$4.25

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought US$57k worth of stock

Price target decreased to US$6.83

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos: FDA Action Makes It Highly Attractive

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Director Judith Dunn has left the company

Price target decreased to US$8.58

We're Hopeful That Seelos Therapeutics (NASDAQ:SEEL) Will Use Its Cash Wisely

Seelos: Superior Data, But Early Stage

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung